Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20151867 | 0.89 | TSHR (0.58) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL12442050 | 0.89 | VEGFA (0.50) | MGLLUSP2ALDH1A1MAPTVEGFA | |
| SCHEMBL5570585 | 0.89 | VEGFA (0.50) | MGLLUSP2ALDH1A1MAPTVEGFA | |
| SCHEMBL19974330 | 0.87 | CYP2D6 (0.53) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL447202 | 0.87 | CYP2D6 (0.53) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL20137136 | 0.86 | CYP2D6 (0.52) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL20503443 | 0.84 | CYP2D6 (0.50) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL8535869 | 0.83 | FAAH (0.60) | MGLLTACR1ALDH1A1GLS | |
| SCHEMBL1657753 | 0.83 | CYP2D6 (0.52) | CYP2D6TSHRMGLLTACR1USP2 | |
| SCHEMBL20567070 | 0.83 | VEGFA (0.53) | MGLLSTSVEGFAEGLN1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332453-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-05-17 | — | — | US | disclosed |
| US-11332453-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-05-17 | — | — | US | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11214557-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-01-04 | — | — | US | disclosed |
| US-11214557-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-01-04 | — | — | US | disclosed |
| CN-108601769-B | Pyrazole compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210206735-A1 | MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206735-A1 | MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| CN-112088001-A | MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190352273-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2019-11-21 | — | — | US | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3377060-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
| US-20210206735-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
| US-11332453-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
| US-20190352273-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
| US-11214557-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | CYP2D6 31/4885TSHR 4703/4885MGLL 21/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | CYP2D6 3916/4885TSHR 4772/4885MGLL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.